23andMe: how to make (a lot of) money out of your customers

被引：6
|
作者：
Jordan, Bertrand [1 ,2 ]
机构：
[1] Aix Marseille Univ, UMR ADES 7268, EFS, CNRS,Espace Eth Mediterraneen,Hop Adultes Timone, F-13385 Marseille 05, France
[2] CoReBio PACA, F-13288 Marseille 09, France
来源：
M S-MEDECINE SCIENCES | 2015年 / 31卷 / 04期
关键词：
D O I：
10.1051/medsci/20153104020
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for targeted drug development. This may be a useful strategy, but it raises a number of questions concerning the privacy of the company's customers and also of adequate compensation when they become valuable currency.
引用
收藏
页码：447 / 449
页数：3
相关论文
共 49 条
12345